BAUSCH + LOMB CORP (BLCO) Stock Price, Quote, News and Overview
NYSE:BLCO - New York Stock Exchange, Inc. - CA0717051076 - Common Stock - Currency: USD
BLCO Quote, Performance and Key Statistics
NYSE:BLCO (2/20/2025, 3:03:02 PM)
16.24
-0.06 (-0.37%)
The current stock price of BLCO is 16.24 USD. In the past month the price decreased by -5.12%. In the past year, price decreased by -7.39%.
BLCO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 29.61 | 44.68B | ||
| COO | COOPER COS INC/THE | 23.87 | 17.63B | ||
| ALGN | ALIGN TECHNOLOGY INC | 21.43 | 14.94B | ||
| SOLV | SOLVENTUM CORP | 17.85 | 12.83B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 31.45 | 6.16B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.69 | 5.64B | ||
| ICUI | ICU MEDICAL INC | 28.86 | 4.01B | ||
| XRAY | DENTSPLY SIRONA INC | 10.33 | 3.80B | ||
| HAE | HAEMONETICS CORP/MASS | 14.97 | 3.18B | ||
| NEOG | NEOGEN CORP | 25.5 | 2.21B | ||
| UFPT | UFP TECHNOLOGIES INC | 37.88 | 2.04B | ||
| RXST | RXSIGHT INC | N/A | 1.22B |
Related stock screener links
About BLCO
Company Profile
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,300 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Company Info
BAUSCH + LOMB CORP
520 Applewood Crescent
Vaughan ONTARIO CA
Employees: 13300
Company Website: https://ir.bausch.com/
Investor Relations: https://ir.bausch.com/
Phone: 19082552864
BAUSCH + LOMB CORP / BLCO FAQ
What is the stock price of BAUSCH + LOMB CORP today?
The current stock price of BLCO is 16.24 USD. The price decreased by -0.37% in the last trading session.
What is the ticker symbol for BAUSCH + LOMB CORP stock?
The exchange symbol of BAUSCH + LOMB CORP is BLCO and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is BLCO stock listed?
BLCO stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for BAUSCH + LOMB CORP stock?
20 analysts have analysed BLCO and the average price target is 21.03 USD. This implies a price increase of 29.47% is expected in the next year compared to the current price of 16.24. Check the BAUSCH + LOMB CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BAUSCH + LOMB CORP worth?
BAUSCH + LOMB CORP (BLCO) has a market capitalization of 5.72B USD. This makes BLCO a Mid Cap stock.
How many employees does BAUSCH + LOMB CORP have?
BAUSCH + LOMB CORP (BLCO) currently has 13300 employees.
What are the support and resistance levels for BAUSCH + LOMB CORP (BLCO) stock?
BAUSCH + LOMB CORP (BLCO) has a support level at 16.14 and a resistance level at 16.41. Check the full technical report for a detailed analysis of BLCO support and resistance levels.
Is BAUSCH + LOMB CORP (BLCO) expected to grow?
The Revenue of BAUSCH + LOMB CORP (BLCO) is expected to grow by 5.47% in the next year. Check the estimates tab for more information on the BLCO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BAUSCH + LOMB CORP (BLCO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BLCO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BLCO, evaluating the profitability, health, valuation and growth aspects
- BAUSCH + LOMB CORP (BLCO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BAUSCH + LOMB CORP (BLCO) Sales and EPS estimates to see what analysts future expectations are.
- BAUSCH + LOMB CORP (BLCO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BAUSCH + LOMB CORP (BLCO) Insider and Institutional Ownership to learn about the owners and their transactions.
- BAUSCH + LOMB CORP (BLCO) Stock Chart to make your own analysis
- BAUSCH + LOMB CORP (BLCO) Latest news and press-releases to stay up to date.
Does BAUSCH + LOMB CORP (BLCO) stock pay dividends?
BLCO does not pay a dividend.
What is the Price/Earnings (PE) ratio of BAUSCH + LOMB CORP (BLCO)?
The PE ratio for BAUSCH + LOMB CORP (BLCO) is 26.19. This is based on the reported non-GAAP earnings per share of 0.62 and the current share price of 16.24 USD. Check the full fundamental report for a full analysis of the valuation metrics for BLCO.
What is the Short Interest ratio of BAUSCH + LOMB CORP (BLCO) stock?
The outstanding short interest for BAUSCH + LOMB CORP (BLCO) is 4.23% of its float. Check the ownership tab for more information on the BLCO short interest.
BLCO Technical Analysis
BLCO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BLCO. BLCO has a medium profitability rating, but doesn't score so well on its financial health evaluation.
BLCO Financial Highlights
Over the last trailing twelve months BLCO reported a non-GAAP Earnings per Share(EPS) of 0.62. The EPS decreased by -16.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.72% | ||
| ROE | -5.59% | ||
| Debt/Equity | 0.7 |
BLCO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to BLCO. The Buy consensus is the average rating of analysts ratings from 20 analysts.
For the next year, analysts expect an EPS growth of 29.89% and a revenue growth 5.47% for BLCO